Analysis of the efficacy of rosuvastatin calcium for different HRCT phenotypes of COPD
Online published: 2016-12-29
Supported by
Research Project of Shanghai Health and Family Planning Commission,20134161;Research on the Training Plan of Excellent Young Talents of Health and Family Planning Commission in Huangpu District of Shanghai from 2013 to 2016
Objective · To investigate the efficacy of rosuvastatin calcium for different high-resolution CT (HRCT) phenotypes of COPD. Methods · Fifty COPD patients were randomly selected and stratified into 3 types, i.e. A, E, M according to emphysema and bronchial wall thickening using HRCT. Based on conventional treatment, patients received 5 mg/d of rosuvastatin calcium for 2 years. Chest HRCT and type stratification were performed prior to treatment. Plasma IL-6 and IL-8 levels and lung function were measured before and after treatment. Results · There were 10 cases of A type, 17 cases of E type, and 23 cases of M type. Differences in IL-8, IL-6, FVC, and FEV1 before and after treatment between 3 types of patients were statistically significant (P < 0.05). Univariate variance analysis showed that differences in the decrease of IL-6 and IL-8 were statistically significant (P = 0.035, P = 0.006), which in A type patients decreased most. The differences in the decrease of FVC and FEV1 were not statistically significant (P=0.154, P = 0.453). Conclusion · Rosuvastatin calcium had efficacy for systemic inflammatory response in COPD patients with different HRCT phenotypes, but was unable to improve pulmonary function. The efficacy for different phenotypes varied.
ZHOU Xi , YAN Jun-hai , ZHAO Chun-liu , HUANG Zhuo-qiong , ZHANG Bai-ying . Analysis of the efficacy of rosuvastatin calcium for different HRCT phenotypes of COPD[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2016 , 36(12) : 1759 . DOI: 10.3969/j.issn.1674-8115.2016.12.016
/
〈 |
|
〉 |